Newsmeme!
Discover News you didn't know existed
T-206
News
Related Video News
No related video news stories found.
Related Videos
No related videos found.
Cell Therapeutics, Inc. to Offer to Repurchase up to $124 Million of Its Notes
Published December 4, 2008, 10:30 pm, PR Newswire via Yahoo! Finance
Cell Therapeutics, Inc. today announced that that its Board of Directors has authorized a "Modified Dutch Auction" tender offer to purchase a portion or all of five series of Convertible Notes as follows:
Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $32.65 Million of Senior Convertible Notes
Published December 4, 2008, 10:00 pm, PR Newswire via Yahoo! Finance
Cell Therapeutics, Inc. today announced that a single institutional investor shall purchase, for $32.65 million, newly issued 10% Convertible Senior Notes due 2011 , with a conversion price of $0.137 per share.
Zevalin Data to be Presented at ASH 2008
Published December 3, 2008, 10:30 pm, PR Newswire via Yahoo! Finance
Cell Therapeutics, Inc. today announced presentations or posters of interest related to Zevalin® to be presented at the 50th Annual Meeting of the American Society of Hematology , December 5-9, 2008 in San Francisco.
Cell Therapeutics, Inc. (CTI) Zevalin Joint Venture Conference Call to be Webcast with Slides
Published November 30, 2008, 10:30 pm, PR Newswire via Yahoo! Finance
On Monday, December 1, 2008, at 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific, Cell Therapeutics, Inc.'s management team will host a conference call to discuss the agreement with Spectrum Pharmaceuticals of Irvine, California to jointly market and develop Zevalin®.
FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review
Published November 30, 2008, 10:30 pm, PR Newswire via Yahoo! Finance
Cell Therapeutics, Inc. announced today that the U.S. Food and Drug Administration has accepted for filing and review, and has granted priority review status for, the supplemental Biologics License Application for use of Zevalin® as consolidation therapy for patients with follicular B-cell non-Hodgkin's lymphoma who achieve a response to first-line therapy.
Cell Therapeutics, Inc. (CTI) to Discuss Zevalin Joint Venture with Spectrum Pharmaceuticals
Published November 27, 2008, 10:30 pm, PR Newswire via Yahoo! Finance
On Monday, December 1, 2008, at 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific, members of Cell Therapeutics, Inc.'s management team will host a conference call to discuss the agreement with Spectrum Pharmaceuticals of Irvine, California to jointly market and develop Zevalin®.
Related News Resources:
> HGH News
News Directory
Get started fast by using a pre-defined news directory category
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |